What is the difference between chemotherapy and herceptin

When started before neoadjuvant or after adjuvant surgery to treat early breast cancer, this drug is usually given for 6 months to a year. For advanced breast cancer, treatment is often given for as long as the drug is helpful. This drug is given into a vein IV.

Herceptin was the original brand name for trastuzumab, but several similar versions called biosimilars are now available as well, including Ogivri, Herzuma, Ontruzant, Trazimera, and Kanjinti.

Another type of trastuzumab, called trastuzumab and hyaluronidase injection Herceptin Hylecta , is also available. It is given as a subcutaneous under the skin shot over a few minutes. Pertuzumab Perjeta : This monoclonal antibody can be given with trastuzumab and chemo, either before or after surgery to treat early-stage breast cancer, or to treat advanced breast cancer. For people getting both of these monoclonal antibodies as part of their treatment, a combination of trastuzumab, pertuzumab, and hyaluronidase Phesgo is also available as a single injection.

It is given as a subcutaneous under the skin shot over several minutes. Margetuximab Margenza : This monoclonal antibody can be used along with chemo to treat advanced breast cancer, typically after at least 2 other drugs that target HER2 have been tried.

An antibody-drug conjugate ADC is a monoclonal antibody linked to a chemotherapy drug. In this case, the anti-HER2 antibody acts like a homing signal by attaching to the HER2 protein on cancer cells, bringing the chemo directly to them. Ado-trastuzumab emtansine Kadcyla or TDM-1 : This antibody-drug conjugate is used by itself to treat early-stage breast cancer after surgery when chemo and trastuzumab were given before surgery, and there was cancer still present at the time of surgery , or to treat advanced breast cancer in women who have already been treated with trastuzumab and chemo.

This drug is given in a vein IV. HER2 is a type of protein known as a kinase. Kinases are proteins in cells that normally relay signals such as telling the cell to grow. Drugs that block kinases are called kinase inhibitors. Lapatinib Tykerb : This drug is a pill taken daily. Lapatinib is used to treat advanced breast cancer, typically along with the chemo drug capecitabine or with certain hormone therapy drugs.

Neratinib Nerlynx : This kinase inhibitor is a pill taken daily. Neratinib is used to treat early-stage breast cancer after a woman has completed one year of trastuzumab, and it is usually given for one year.

It can also be given along with the chemo drug capecitabine to treat people with metastatic disease, typically after at least 2 other anti-HER2 targeted drugs have been tried. Tucatinib Tukysa : This kinase inhibitor is taken as pills, typically twice a day. Tucatinib is used to treat advanced breast cancer, after at least one other anti-HER2 targeted drug has been tried.

It is typically given along with trastuzumab and the chemo drug capecitabine. The side effects of HER2 targeted drugs are often mild, but some can be serious.

Discuss what you can expect with your doctor. The monoclonal antibodies and antibody-drug conjugates can sometimes cause heart damage during or after treatment. This can lead to congestive heart failure. For most but not all women, this effect lasts a short time and gets better when the drug is stopped. The risk of heart problems is higher when these drugs are given with certain chemo drugs that also can cause heart damage, such as doxorubicin Adriamycin and epirubicin Ellence.

Questions to Ask about Your Treatment. Feelings and Cancer. Adjusting to Cancer. Day-to-Day Life. Support for Caregivers. Questions to Ask About Cancer.

Choices for Care. Talking about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Managing Cancer Care. Finding Health Care Services. Advance Directives. Using Trusted Resources.

Coronavirus Information for Patients. Clinical Trials during Coronavirus. Adolescents and Young Adults with Cancer. Emotional Support for Young People with Cancer. Cancers by Body Location. Late Effects of Childhood Cancer Treatment. Pediatric Supportive Care.

Rare Cancers of Childhood Treatment. Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research. Intramural Research. Extramural Research. Cancer Research Workforce. Partners in Cancer Research. What Are Cancer Research Studies. Research Studies. Get Involved. Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer. Cancer Prevention Research. Cancer Treatment Research.

Cancer Health Disparities. Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. For this quick test, you lie still for a few minutes while a device that gives off sound waves is briefly placed on your ribs, over your heart.

There is no radiation exposure with this test. A MUGA scan takes about an hour. In this test, a tiny amount of radioactive material is injected into a vein in your arm. This material temporarily hooks onto your red blood cells.

You lie still while a special camera that can detect the radioactive material takes pictures of the blood flow through your heart as it beats. Your doctor will continue to monitor your heart function while you are receiving Herceptin, as well as after you complete treatment.

Herceptin may cause inflammation of the lungs, which can be life-threatening. Symptoms include trouble breathing, cough, tiredness, and fluid in the lungs. Herceptin Hylecta chemical name: trastuzumab and hyaluronidase-oysk is an injectable form of Herceptin. It is a combination of Herceptin and hyaluronidase, an enzyme that helps your body use the Herceptin. Traditional Herceptin is given by intravenous IV infusion, which means the medicine is delivered directly into your bloodsteam through an IV or port.

Herceptin Hylecta is given subcutaneously, which means it is injected under your skin using a hypodermic needle, much like a vaccine. The injection takes about 2 to 5 minutes and is given in your thigh, alternating between left and right for each dose. Herceptin Hylecta is given at a fixed dose of milligrams, while the dose of IV Herceptin is based on your weight.

You can receive a Herceptin Hylecta injection at an infusion center along with a chemotherapy regimen. Herceptin Hylecta is approved to treat HER2-positive breast cancer that has spread to the lymph nodes node-positive , or is not in the lymph nodes but is considered to be at high risk of recurrence:. Like Herceptin, Herceptin Hylecta can cause side effects, some of them severe.

Common Herceptin Hylecta side effects include:. Like Herceptin, less common but more severe side effects of Herceptin Hylecta include weakening of the heart muscle and other heart problems , as well as serious lung problems. Also like Herceptin, women who are pregnant or planning to get pregnant should not be treated with Herceptin Hylecta.

Herceptin Hylecta can harm the developing fetus. Learn more about Herceptin Hylecta. This means that it is made from living organisms, in this case a protein from a mouse cell. A monoclonal antibody is a type of protein made in the lab that can bind to substances in the body, including cancer cells.

Each monoclonal antibody is made so that it binds only to one substance. Herceptin binds to the HER2 receptor proteins in cancer cells. Because they are made from living organisms, biologic drugs are much more complex to make than conventional drugs that are made from a mixture of chemicals. The chemical structure of conventional drugs can be easily identified and duplicated, which is why there are so many generic drugs on the market. A biosimilar is a new type of biologic drug. A biosimilar is almost identical to a biologic drug that is already approved by the FDA or similar organizations in other countries.

Biologic drugs can be very sensitive to changes in the manufacturing process. If one small step is done differently, the biosimilar may have very different effects than the original biologic drug. So, the U. Food and Drug Administration FDA requires that any biosimilar drug go through the same rigorous clinical trials that original biologic drugs do before the agency will approve the biosimilar.